Literature DB >> 6434313

Financial analysis, personnel planning and organizational requirements for the installation of a kidney lithotripter in a urologic department.

K Miller, G Fuchs, J Rassweiler, F Eisenberger.   

Abstract

The first clinical experiences with extracorporeal shockwave lithotripsy (ESWL)--the method of choice in noninvasive treatment of renal calculi--were so encouraging that more ESWL units are now being installed and a still larger number can be predicted. A cost-efficiency analysis shows that, in spite of high investment costs, a net saving of about DM 4,599 (deutsche marks) can be figured for each 'ESWL patient' compared to the expenses of an open operation. This benefit is due to the reduction of disability time, hospital stay and dialysis cases. For the management of an ESWL unit a trained team of urologists and anesthesiologists, as well as a clinic with an 'operative background' is necessary.

Entities:  

Mesh:

Year:  1984        PMID: 6434313     DOI: 10.1159/000463795

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  4 in total

1.  Extracorporeal shock wave lithotripsy: the first 50 patients treated in Britain.

Authors:  J E Wickham; D R Webb; S R Payne; M J Kellet; G Watkinson; H N Whitfield
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-20

2.  Experiments with extracorporeal shock wave nephrolithotripsy.

Authors:  A A Li; N I Alekseyeva; L N Gerasimov
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

3.  Clinical comparison of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy in treating renal calculi.

Authors:  N Mays; S Challah; S Patel; E Palfrey; R Creeser; P Vadera; P Burney
Journal:  BMJ       Date:  1988-07-23

Review 4.  The Role of Ferroptosis in Blood-Brain Barrier Injury.

Authors:  Yao Zhao; Ying Liu; Yunfei Xu; Kexin Li; Lin Zhou; Haoduo Qiao; Qing Xu; Jie Zhao
Journal:  Cell Mol Neurobiol       Date:  2022-02-01       Impact factor: 5.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.